Globus Medical, Inc. · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 19.0% margin the price requires 2.9% 3y revenue CAGR against 5.8% consensus, a cushion of +2.6pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. Unaffected; the narrative overstates the growth required.
Breaks if: the negative Q3 call (2026-11-07) becomes a guide cut. We re-check this against analyst estimates every evening.
10 years, at a 19% margin analysts expect
+4.5%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
6 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 178% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 10, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the very bottom of the published model range, rejecting all four bull cases to trade 23% below the median target, which shows the market firmly assumes the recent 16.7% growth will collapse toward a 3% pace.
Does the 10% U.S. spine market-share gain represent a durable structural shift that keeps overall revenue growth in the mid-teens, and the available unit volume data can actually measure this.
What the price refuses to pay for, and the full reconstruction, on the GMED quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names